Common use of Additional Information and Where to Find It Clause in Contracts

Additional Information and Where to Find It. This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. This communication may be deemed to be solicitation material in respect of the Merger. In connection with the proposed transaction, the Company plans to file a proxy statement with the SEC and Canadian securities regulatory authorities. STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN) AND OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTION THAT THE COMPANY WILL FILE WITH THE SEC AND CANADIAN SECURITIES REGULATORY AUTHORITIES WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. Stockholders and investors will be able to obtain free copies of the proxy statement and other relevant materials (when they become available) and other documents filed by the Company at the SEC’s website at xxx.xxx.xxx and the website of the Canadian securities regulatory authorities at xxx.xxxxx.xxx. Copies of the proxy statement (when they become available) and the filings that will be incorporated by reference therein may also be obtained, without charge, by contacting the Company’s Investor Relations department at xx@xxxxxxxxxxxxx.xxx or (000) 000-0000.

Additional Information and Where to Find It. This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. This communication may be deemed to be solicitation material in respect of the Merger. In connection with the proposed transaction, the Company plans to file a proxy statement with the SEC and Canadian securities regulatory authorities. STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN) AND OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTION THAT THE COMPANY WILL FILE WITH THE SEC AND CANADIAN SECURITIES REGULATORY AUTHORITIES WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. Stockholders and investors will be able to obtain free copies of the proxy statement and other relevant materials (when they become available) and other documents filed by the Company at the SEC’s 's website at xxx.xxx.xxx and the website of the Canadian securities regulatory authorities at xxx.xxxxx.xxx. Copies of the proxy statement (when they become available) and the filings that will be incorporated by reference therein may also be obtained, without charge, by contacting the Company’s 's Investor Relations department at xx@xxxxxxxxxxxxx.xxx or (000) 000-0000.

Additional Information and Where to Find It. This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. This communication may be deemed to be solicitation material in respect of the Mergerproposed merger involving Tyler Technologies and NIC. In connection with the proposed transactionmerger, the Company NIC plans to file a proxy statement with the SEC and Canadian securities regulatory authoritiesSEC. STOCKHOLDERS OF THE COMPANY NIC ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN) AND OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTION WITH TYLER TECHNOLOGIES THAT THE COMPANY NIC WILL FILE WITH THE SEC AND CANADIAN SECURITIES REGULATORY AUTHORITIES WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. Stockholders and investors will be able to obtain free copies of the proxy statement and other relevant materials (when they become available) and other documents filed by the Company NIC at the SEC’s website at xxx.xxx.xxx and the website of the Canadian securities regulatory authorities at xxx.xxxxx.xxxxxx.xxx.xxx. Copies of the proxy statement (when they become available) and the filings that will be incorporated by reference therein may also be obtained, without charge, by contacting on the Company’s Investor Relations department website at xx@xxxxxxxxxxxxx.xxx or (000) 000-0000xx.xxxx.xxx.

Additional Information and Where to Find It. This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. This communication may be deemed to be solicitation material in respect of the Merger. In connection with the proposed transaction, Amedisys, Inc. (“Amedisys”) will file relevant materials with the Company plans to file United States Securities and Exchange Commission (the “SEC”), including a proxy statement with the SEC and Canadian securities regulatory authoritieswhich will be mailed to stockholders of Amedisys. STOCKHOLDERS INVESTORS AND SECURITY HOLDERS OF THE COMPANY AMEDISYS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING AND ANY AMENDMENTS OR SUPPLEMENTS THERETO AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN) THERETO, AND OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTION THAT THE COMPANY WILL FILE BE FILED WITH THE SEC CAREFULLY AND CANADIAN SECURITIES REGULATORY AUTHORITIES IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTIONINFORMATION. Stockholders Investors and investors security holders will be able to obtain free copies of the proxy statement and other relevant materials (when they become available) and other documents filed with the SEC by Amedisys through the website maintained by the Company SEC at the SEC’s website at xxx.xxx.xxx and the website of the Canadian securities regulatory authorities at xxx.xxxxx.xxxhxxx://xxx.xxx.xxx. Copies of the proxy statement (when they become available) and documents filed with the filings that SEC by Amedisys will be incorporated by reference therein may also be obtained, without charge, available free of charge on Amedisys’s internet website at hxxxx://xxxxxxxxx.xxxxxxxx.xxx or by contacting the CompanyAmedisys’s Investor Relations investor relations department at xx@xxxxxxxxxxxxx.xxx or (000) 000-0000IX@xxxxxxxx.xxx.